<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04984980</url>
  </required_header>
  <id_info>
    <org_study_id>2020-176-2096</org_study_id>
    <nct_id>NCT04984980</nct_id>
  </id_info>
  <brief_title>Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer</brief_title>
  <official_title>Efficacy and Safety of the Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Initially Unresectable Biliary Tract Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study design: Prospective, single-arm, single-center phase II clinical study; Primary&#xD;
      endpoint: Conversion rate; Secondary endpoints: Safety, disease control rate, disease-free&#xD;
      survival, and overall survival; Main characteristics of enrolled patients: Patients with&#xD;
      initially unresectable biliary tract cancer; Interventions: Combination of Gemcitabine,&#xD;
      Oxaliplatin, Sintilimab and Bevacizumab; Sample size: 34 patients; Treatment until: 1.&#xD;
      successfully conversed to resectable disease 2. progressed disease 3. intolerable toxicity 4.&#xD;
      patient requests withdrawal; Research process: In this study, patients who met the inclusion&#xD;
      criteria were evaluated at the end of every 3 weeks of treatment, up to surgical treatment or&#xD;
      disease progression; Safety evaluation: Evaluate adverse reactions according to CTCAE 4.0;&#xD;
      Follow up: 12 months after the last case was enrolled.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Conversion rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Conversion rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety：the incidence of adverse events and serious adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidence of adverse events and serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>disease control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progress-free survival</measure>
    <time_frame>12 weeks</time_frame>
    <description>progress-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>12 weeks</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Biliary Tract Carcinoma</condition>
  <condition>Initially Unresectable</condition>
  <arm_group>
    <arm_group_label>combined treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab Gemcitabine: 1000mg/m^2, iv, d1, d8, q3w Oxaliplatin: 100mg/m^2, iv, d1, q3w Sintilimab: 200mg, iv, d1, q3w Bevacizumab: 5mg/kg, d1, q3w</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab</intervention_name>
    <description>Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab</description>
    <arm_group_label>combined treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 and ≤80 years;&#xD;
&#xD;
          2. ECOG 0~1;&#xD;
&#xD;
          3. Histologically or cytologically confirmed carcinoma of the bile duct or gallbladder;&#xD;
&#xD;
          4. Imaging assessment of disease stage III/IVA/any TN1M0*;&#xD;
&#xD;
          5. The main organs have good functions and the examination indexes meet the following&#xD;
             requirements:&#xD;
&#xD;
          6. Blood routine test:&#xD;
&#xD;
             Hemoglobin ≥90 g/L (no blood transfusion within 14 days); Neutrophils count&#xD;
             ≥1.5×10^9/L; Platelet count ≥80×10^9/L;&#xD;
&#xD;
          7. Biochemical tests:&#xD;
&#xD;
             Total bilirubin ≤2×ULN (upper limit of normal value); Blood alanine aminotransferase&#xD;
             (ALT) or blood aspartate aminotransferase (AST) ≤ 2.5×ULN; Endogenous creatinine&#xD;
             clearance rate ≥ 50 mL /min (Cockcroft-Gault formula);&#xD;
&#xD;
          8. Voluntarily signed the informed consent;&#xD;
&#xD;
          9. Good compliance and family members are willing to cooperate with follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other uncured malignancies;&#xD;
&#xD;
          2. Pregnant or lactating women, if the subject becomes pregnant during the study period,&#xD;
             should withdraw from the clinical trial;&#xD;
&#xD;
          3. Previous anti-tumor therapy for the disease in this study;&#xD;
&#xD;
          4. Participated in other drug clinical trials within one month;&#xD;
&#xD;
          5. Patients with known history of other systemic serious diseases before screening;&#xD;
&#xD;
          6. Long-term unhealed wounds or incomplete healed fractures;&#xD;
&#xD;
          7. Have a history of organ transplantation;&#xD;
&#xD;
          8. Abnormal blood coagulation, with bleeding tendency (14 days before randomization must&#xD;
             meet: INR within the normal range without the use of anticoagulants); Patients treated&#xD;
             with anticoagulants or vitamin K antagonists such as warfarin, heparin or their&#xD;
             analogs; The use of low-dose warfarin (1 mg orally, once daily) or low-dose aspirin&#xD;
             (not more than 100 mg daily) for prophylactic purposes is permitted, provided that INR&#xD;
             is less than 1.5;&#xD;
&#xD;
          9. The incidence of arterial/venous thrombosis events in the previous year, such as&#xD;
             cerebrovascular accident (including temporary ischemic attack), deep venous thrombosis&#xD;
             and pulmonary embolism, was screened;&#xD;
&#xD;
         10. People with a history of psychotropic substance abuse and unable to get rid of it or&#xD;
             with mental disorders; Have a history of immunodeficiency, or other acquired or&#xD;
             congenital immunodeficiency diseases, or have a history of organ transplantation;&#xD;
&#xD;
        12. Concomitant diseases that, in the Investigator's judgment, seriously endanger patient&#xD;
        safety or affect patient completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lu Wang, M.D.</last_name>
    <phone>+86-18121299357</phone>
    <email>w.lr@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lu Wang</last_name>
      <phone>+8618121299357</phone>
      <email>w.lr@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>July 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

